Cargando…

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy

SIMPLE SUMMARY: Osimertinib has become the standard of care for the first-line treatment of EGFR-mutant NSCLC patients. The aim of this current translational research study was to assess the clinical relevance of liquid biopsy in 47 patients receiving osimertinib. Effects on circulating tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kallergi, Galatea, Kontopodis, Emmanouil, Ntzifa, Aliki, Jordana-Ariza, Núria, Karachaliou, Niki, Pantazaka, Evangelia, Charalambous, Haris A., Psyrri, Amanda, Tsaroucha, Emily, Boukovinas, Ioannis, Koumarianou, Anna, Hatzidaki, Dora, Lianidou, Evi, Georgoulias, Vassilis, Rosell, Rafael, Kotsakis, Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946716/ https://www.ncbi.nlm.nih.gov/pubmed/35326725 http://dx.doi.org/10.3390/cancers14061574

Ejemplares similares

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
por: Ntzifa, Aliki, et al.
Publicado: (2021)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer
por: Markou, Athina, et al.
Publicado: (2021)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
por: Kallergi, G., et al.
Publicado: (2018)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization
por: Kallergi, Galatea, et al.
Publicado: (2019)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook
por: Lianidou, Evi
Publicado: (2021)

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
por: Katsarou, Spyridoula D., et al.
Publicado: (2022)

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
por: Yaghoubi Naei, Vahid, et al.
Publicado: (2023)

Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients
por: Pantazaka, Evangelia, et al.
Publicado: (2021)

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer
por: Zafeiriadou, A., et al.
Publicado: (2022)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer
por: Markou, A. N., et al.
Publicado: (2023)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
por: Lim, Minji, et al.
Publicado: (2018)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology
por: Vardas, Vasileios, et al.
Publicado: (2023)

Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients
por: Roumeliotou, Argyro, et al.
Publicado: (2022)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
por: Buszka, Karolina, et al.
Publicado: (2022)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group
por: Kentepozidis, Nikolaos, et al.
Publicado: (2018)

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection
por: Markou, Α., et al.
Publicado: (2022)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1
por: Markou, Athina N., et al.
Publicado: (2021)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
por: Agelaki, Sofia, et al.
Publicado: (2016)

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
por: Carvalho, Ângela, et al.
Publicado: (2021)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
por: Strati, Areti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h1e1ncfg6m2cnhebscq1jlfk80